Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8+ T cell-mediated cell death

Immunology Letters

Volumn 122, Issue 1, 2009, Pages 58-67

  Kim, Jin Hee ^a   Kang, Tae Heung ^a   Noh, Kyung Hee ^a   Bae, Hyun Cheol ^a   Kim, Seok Ho ^a   Yoo, Young Do ^a,b   Seong, Seung Yong ^c   Kim, Tae Woo ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

BIM; Dendritic cell; HPV E7; Immunotherapy; Sig E7 LAMP 1; siRNA

Indexed keywords

BIM PROTEIN; DENDRITIC CELL VACCINE; SMALL INTERFERING RNA; VIRUS ANTIGEN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CELL KILLING; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; FEMALE; GENETIC TRANSFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; VACCINES;

EID: 59649107188     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.12.006     Document Type: Article

References (33)

1. Engleman E.G. Dendritic cell-based cancer immunotherapy. Semin Oncol 30 (2003) 23-29
2. Figdor C.G., de Vries I.J., Lesterhuis W.J., and Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 10 (2004) 475-480
3. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15 (2003) 138-147
4. Wang T.L., Ling M., Shih I.M., Pham T., Pai S.I., Lu Z., et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 7 (2000) 726-733
5. + T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 164 (2000) 3095-3101
6. Liu K., Iyoda T., Saternus M., Kimura Y., Inaba K., and Steinman R.M. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196 (2002) 1091-1097
7. Kim T.W., Hung C.F., Boyd D., Juang J., He L., Kim J.W., et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 171 (2003) 2970-2976
8. Kim T.W., Hung C.F., Ling M., Juang J., He L., Hardwick J.M., et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 112 (2003) 109-117
9. Kang T.H., Lee J.H., Noh K.H., Han H.D., Shin B.C., Choi E.Y., et al. Enhancing dendritic cell vaccine potency by combining a SiBAK + BAX-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer 120 (2007) 1696-1703
10. Peng S., Kim T.W., Lee J.H., Yang M., He L., Hung C.F., et al. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 16 (2005) 584-593
11. Hou W.S., and Van Parijs L. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol 5 (2004) 583-589
12. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 5 (2005) 189-200
13. Zong W.X., Lindsten T., Ross A.J., MacGregor G.R., and Thompson C.B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15 (2001) 1481-1486
14. Opferman J.T., and Korsmeyer S.J. Apoptosis in the development and maintenance of the immune system. Nat Immunol 4 (2003) 410-415
15. - mediated mitochondrial apoptosis. Mol Cell 8 (2001) 705-711
16. Kang T.H., Lee J.H., Bae H.C., Noh K.H., Kim J.H., Song C.K., et al. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol Lett 106 (2006) 126-134
17. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176 (1992) 1693-1702
18. Hung C.F., Cheng W.F., Hsu K.F., Chai C.Y., He L., Ling M., et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61 (2001) 3698-3703
19. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 (1996) 21-26
20. Ronchese F., and Hermans I.F. Killing of dendritic cells: a life cut short or a purposeful death?. J Exp Med 194 (2001) F23-F26
21. Medema J.P., Schuurhuis D.H., Rea D., van Tongeren J., de Jong J., Bres S.A., et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 194 (2001) 657-667
22. Russell J.H., and Ley T.J. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20 (2002) 323-370
23. + T cells in vivo. Proc Natl Acad Sci USA 103 (2006) 147-152
24. Oehen S., and Brduscha-Riem K. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol 161 (1998) 5338-5346
25. Langenkamp A., Casorati G., Garavaglia C., Dellabona P., Lanzavecchia A., and Sallusto F. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol 32 (2002) 2046-2054
26. Jacotot E., Costantini P., Laboureau E., Zamzami N., Susin S.A., and Kroemer G. Mitochondrial membrane permeabilization during the apoptotic process. Ann N Y Acad Sci 887 (1999) 18-30
27. Degli Esposti M., and Dive C. Mitochondrial membrane permeabilisation by Bax/Bak. Biochem Biophys Res Commun 304 (2003) 455-461
28. Waterhouse N.J., Sedelies K.A., Browne K.A., Wowk M.E., Newbold A., Sutton V.R., et al. A central role for Bid in granzyme B-induced apoptosis. J Biol Chem 280 (2005) 4476-4482
29. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, et al. 1999; 400:886-91.
30. Chen M., Huang L., and Wang J. Deficiency of Bim in dendritic cells contributes to overactivation of lymphocytes and autoimmunity. Blood 109 (2007) 4360-4367
31. Jorgensen T.N., McKee A., Wang M., Kushnir E., White J., Refaeli Y., et al. Bim and Bcl-2 mutually affect the expression of the other in T cells. J Immunol 179 (2007) 3417-3424
32. Kim T.W., Lee J.H., He L., Boyd D.A., Hardwick J.M., Hung C.F., et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65 (2005) 309-316
33. Derby M., Alexander-Miller M., Tse R., and Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 166 (2001) 1690-1697